Maxim down on melanoma Phase III data

On Monday, MAXM dropped $2.90 (49%) to $3.04 on 17.5 million shares after its Ceplene plus interleukin-2 (IL-2) missed the primary endpoint in an international Phase III trial (M104) in 230 advanced m...